Autopsy report · NCT01614925

Safety and Efficacy of Periodontal Surgery in Supra-alveolar-type Defects With or Without Straumann® Emdogain

“Due to change in strategy and decision not to expand indication.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 35 participants enrolled.
• Results were posted on the registry 6 years 2 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Institut Straumann AG

Sponsor type

Industry

Conditions

Periodontal Attachment Loss; Periodontal Diseases

Interventions

Emdogain; Periodontal surgery

Participants

35

Sites

1

Countries

United States

Trials that died the same way

• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (71% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (70% match in meaning)
• Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
  “Change in strategy.” (66% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (66% match in meaning)
• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
  “Strategy Change” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.